Publisher
Springer Science and Business Media LLC
Reference8 articles.
1. Tah V, Orlans HO, Hyer J, Casswell E, Din N, Sri Shanmuganathan V, et al. Anti-VEGF therapy and the retina: an update. J Ophthalmol. 2015;2015:627674. https://doi.org/10.1155/2015/627674.
2. Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD. Novartis. 2020. https://www.novartis.com/news/media-releases/novartis-announces-fda-filing-acceptance-and-priority-review-brolucizumab-rth258-patients-wet-am.
3. Sharma A, Kumar N, Kuppermann BD, Bandello F. Brolucizimab—leading an era of structural revolution for long-term VEGF suppression. Eye. 2020;34:611–3.
4. Lanzetta P, Loewenstein A, and The Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255:1259–73.
5. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127:72–84.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献